Effects of Verapamil on the Pharmacokinetics and Blood Glucose-Lowering Efficacy of Saxagliptin in Normal and Streptozotocin-Nicotinamide-Induced Type 2 Diabetic Male Rats
Canadian Journal of Physiology and Pharmacology · 04.11.2026
DOI: 10.1139/cjpp-2026-0210 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Physiology and Pharmacology, online erschienen am 04.11.2026. Verfasst von Orkun Atik und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Afyon Kocatepe, Department of Pharmacology and Toxicology, Afyonkarahisar, Turkey; oatik@aku.edu.tr.
Abstract (Originalsprache)
Cardiovascular side effects are the leading cause of hospitalization/death in patients with diabetes. Saxagliptin is recommended for glycemic control in patients with Type-2-Diabetes-Mellitus (T2DM), while verapamil is preferred for cardiovascular disease. Although verapamil has been reported to exert blood glucose-lowering effects, its potential influence on the pharmacokinetics and glucose-lowering efficacy of saxagliptin has not yet been fully elucidated. This study aimed to investigate the effect of verapamil on the pharmacokinetics and blood glucose-lowering activity of saxagliptin in healthy and T2DM-model rats. Pharmacokinetic profiles of oral administration of saxagliptin (20 mg/kg) in rats with four groups (two healthy and two diabetic), with or without pretreatment of verapamil (10 mg/kg/day, PO, for 7 days), were examined. Also, blood glucose levels were analyzed to determine pharmacodynamic differences. Verapamil significantly increased the peak plasma concentration of saxagliptin in healthy and diabetic rats (from 4.8±1.07 to 6.96±1.22 μg/mL and from 6.05±1.68 to 8.24±1.2 μg/mL, respectively). Additionally, it was determined that blood glucose levels decreased with saxagliptin administration in all groups, and the decrease was higher in the verapamil-pretreated groups. The findings of this study may assist identify the best pharmacological combination effects of verapamil and saxagliptin in the treatment of diabetes.
Autor:innen und Institutionen
- University of Afyon Kocatepe, Department of Pharmacology and Toxicology, Afyonkarahisar, Turkey; oatik@aku.edu.tr.
- University of Afyon Kocatepe, Department of Pharmacology and Toxicology, Afyonkarahisar, Turkey; ybirdane@aku.edu.tr.
Zitieren
APA
Atik, O., & Birdane, Y. O. (2026). Effects of Verapamil on the Pharmacokinetics and Blood Glucose-Lowering Efficacy of Saxagliptin in Normal and Streptozotocin-Nicotinamide-Induced Type 2 Diabetic Male Rats. Canadian Journal of Physiology and Pharmacology. https://doi.org/10.1139/cjpp-2026-0210
Vancouver
Atik O, Birdane YO. Effects of Verapamil on the Pharmacokinetics and Blood Glucose-Lowering Efficacy of Saxagliptin in Normal and Streptozotocin-Nicotinamide-Induced Type 2 Diabetic Male Rats. Canadian Journal of Physiology and Pharmacology. 2026. doi:10.1139/cjpp-2026-0210
BibTeX
@article{Atik2026,
author = {Atik, Orkun and Birdane, Yavuz Osman},
title = {Effects of Verapamil on the Pharmacokinetics and Blood Glucose-Lowering Efficacy of Saxagliptin in Normal and Streptozotocin-Nicotinamide-Induced Type 2 Diabetic Male Rats},
journal = {Canadian Journal of Physiology and Pharmacology},
year = {2026},
doi = {10.1139/cjpp-2026-0210}
}
EUVIMED